# Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)

> **NCT06943235** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 60 (estimated)

## Conditions studied

- Limited Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Probiotics
- **RADIATION:** concurrent Hyperfractionated Radiotherapy
- **DRUG:** Immunotherapy

## Key facts

- **NCT ID:** NCT06943235
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-25
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06943235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06943235, "Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)". Retrieved via AI Analytics 2026-08-09 from https://api.ai-analytics.org/clinical/NCT06943235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*